The market is segmented based on Segmentation, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastinal Tumours, Mesothelioma and Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multikinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Speciality Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others) - Industry Trends and Forecast to 2032
.
The Global Lung Cancer Therapeutics Market size was valued at USD 33.19 USD Billion in 2024.
The Global Lung Cancer Therapeutics Market is projected to grow at a CAGR of 10.41% during the forecast period of 2025 to 2032.
The major players operating in the market include Church &, Dwight Co.Inc. , GlaxoSmithKline plc. , Pfizer Inc. , Sun Pharmaceutical Industries Ltd. , Takeda Pharmaceutical Company Limited , ONO PHARMACEUTICAL CO.Ltd. , F. Hoffmann-La Roche Ltd , Novartis AG , Lily. , AstraZeneca , Boehringer Ingelheim International GmbH , Merck &, Co.Inc. , CELGENE CORPORATION , Sanofi , Johnson &, Johnson ServicesInc. , Dr. Reddy&rsquo,s Laboratories Ltd. , ALLERGAN , Teva Pharmaceutical Industries Ltd. , and Bristol-Myers Squibb Company , .
The market report covers data from the North America.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.